BNP Paribas Financial Markets Raises Holdings in IQVIA Holdings Inc. (NYSE:IQV)

BNP Paribas Financial Markets grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 66.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 476,442 shares of the medical research company's stock after buying an additional 190,360 shares during the quarter. BNP Paribas Financial Markets owned 0.26% of IQVIA worth $93,626,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Smith Group Asset Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at approximately $1,616,000. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. acquired a new stake in IQVIA in the fourth quarter valued at $941,000. Fifth Third Bancorp lifted its holdings in IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS increased its holdings in shares of IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after acquiring an additional 2,700 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.8 %

Shares of IQV opened at $152.31 on Tuesday. The firm's 50-day moving average is $166.75 and its two-hundred day moving average is $190.17. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $26.85 billion, a P/E ratio of 20.31, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IQV shares. HSBC cut IQVIA from a "buy" rating to a "hold" rating and decreased their target price for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Barclays restated an "equal weight" rating and issued a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Finally, Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $237.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.